EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

The clearance of a single i.v. bolus of recombinant human erythropoietin from the serum of patients with myelodysplastic syndromes and its effects on erythropoiesis



The clearance of a single i.v. bolus of recombinant human erythropoietin from the serum of patients with myelodysplastic syndromes and its effects on erythropoiesis



Experimental Hematology 19(7): 613-616



The serum erythropoietin (EPO) concentrations in patients with myelodysplasia (MDS) varies widely at similar hemoglobin concentrations, although the reasons for this variation are unclear. We have studied the pharmacokinetics of an i.v. bolus of recombinant human EPO in ten subjects with myelodysplasia. Basal serum EPO concentrations varied from 210 to 5984 mU/ml. Plasma half-time clearance (t1/2) varied from 3.9 to 20.0 h. A significant positive correlation was found between t1/2 and basal EPO concentrations. An increase in immature peripheral blood reticulocytes was found on days 1 and 2 after EPO treatment; this may represent either an effect on hemopoiesis or on reticulocytes release from the bone marrow.

(PDF emailed within 1 workday: $29.90)

Accession: 007877795

Download citation: RISBibTeXText

PMID: 1716588



Related references

Serum erythropoietin and erythropoiesis in patients with myelodysplastic syndromes. European Journal of Haematology 44(1): 30-32, 1990

High-dose (40,000 IU twice/week) alpha recombinant human erythropoietin as single agent in low/intermediate risk myelodysplastic syndromes: a retrospective investigation on 133 patients treated in a single institution. American Journal of Hematology 86(9): 762-767, 2011

Serum erythropoietin level and marrow erythroid infiltration predict response to recombinant human erythropoietin in myelodysplastic syndromes. Haematologica 78(2): 118-122, 1993

Recombinant human erythropoietin in patients with myelodysplastic syndromes. Leukemia 5(5): 432-436, 1991

Recombinant human erythropoietin epo for patients with myelodysplastic syndromes mds. European Journal of Clinical Investigation 20(2 PART 2): A57, 1990

Recombinant human granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin may improve anemia in selected patients with myelodysplastic syndromes. American Journal of Hematology 44(4): 229-236, 1993

Therapy with recombinant human erythropoietin in patients with myelodysplastic syndromes. Leukemia Research 18(10): 769-776, 1994

A New Long Noncoding RNA ALB Regulates Autophagy by Enhancing the Transformation of LC3BI to LC3BII during Human Lens Development. Molecular Therapy. Nucleic Acids 9: 207-217, 2017

Therapy with human recombinant erythropoietin in patients with myelodysplastic syndromes. British Journal of Haematology 81(4): 628-630, 1992

Heterogeneity of responsiveness to recombinant human erythropoietin in patients with myelodysplastic syndromes. Acta Haematologica Japonica 53(6): 866-872, 1990

Treatment with mycophenolate mofetil followed by recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes resistant to erythropoietin treatment. Haematologica 95(2): 339-340, 2010

Treatment of patients with myelodysplastic syndromes using human recombinant erythropoietin: Proposal for a therapeutic protocol. Biologia & Clinica Hematologica 14(1): 17-23, 1992

Efficacy and safety of recombinant human erythropoietin r huepo in anemic patients with myelodysplastic syndromes. Leukemia Research 15(SUPPL): 13, 1991

Current use of recombinant human erythropoietin in the management of symptomatic anaemia in patients with myelodysplastic syndromes. Sangre (Saragossa) 39(2): 105-110, 1994

Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study. Annals of Hematology 93(8): 1413-1420, 2014